Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 7,009 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urologic Diseases Clear all
Terminated Not applicable Interventional Results available

Connected Catheter - Safety and Effectiveness Study

NCT04059159
View directory record Official record
Conditions
Neurogenic Bladder, Urinary Retention, Urologic Diseases
Interventions
Connected Catheter
Device
Lead sponsor
Spinal Singularity
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Downey, California • San Diego, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Low-moderate Intensity Pedaling During Immunotherapy Administration

NCT04127318
View directory record Official record
Conditions
Cancer of Skin, Cancer of Kidney, Cancer of Bladder, Exercise, Aerobic, Immunotherapy
Interventions
Pedaling Group
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

NCT00664027
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
RTA 402 (Bardoxolone Methyl)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Effect of Adipokines in Hemodialysis Patients

NCT01301027
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Denver, Colorado • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting Phase 1 Interventional

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413
View directory record Official record
Conditions
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions
IDE892, IDE397
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

NCT03804879
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Nidufexor, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

NCT00462982
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Azusa, California • Los Angeles, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

NCT01764854
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease Stage 5, ESRD
Interventions
AZD1722 (in-patient), Placebo (in-patient), AZD1722 (out-patient), Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Tempe, Arizona • Denver, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 17, 2026, 8:20 AM EDT
Completed No phase listed Observational

A Clinical Decision Support Trial to Reduce Intraoperative Hypotension

NCT04062994
View directory record Official record
Conditions
Hypotension, Acute Kidney Injury
Interventions
Nudge to reduce intraoperative hypotension
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus

NCT03774394
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Interventions
Clopidogrel, Clopidogrel active metabolite
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting Not applicable Interventional

TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.

NCT06369922
View directory record Official record
Conditions
Stress Incontinence Female, Urinary Incontinence, Urinary Incontinence,Stress, Pain, Pain Acute
Interventions
TENS, Control TENS
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Active, not recruiting Phase 1 Interventional

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

NCT05614102
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Denver, Colorado • Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Enrolling by invitation No phase listed Observational

Blood Volume Monitoring Via Critline in Volume Overload: Hospitalization and Readmission

NCT07866872
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Volume Overload
Interventions
Relative Blood Volume Monitoring (RBVM)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma

NCT02687139
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
18F-DCFPyL, PET/CT
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting Phase 1 Interventional

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NCT06465069
View directory record Official record
Conditions
Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions
LY4052031, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer

NCT00052637
View directory record Official record
Conditions
Bladder Cancer
Interventions
hexaminolevulinate, biopsy, cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC

NCT00169741
View directory record Official record
Conditions
Renal Calculi
Interventions
Renogram
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

NCT01750294
View directory record Official record
Conditions
Chronic Kidney Disease, Poorly-Controlled Hypertension
Interventions
Chlorthalidone
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 17, 2026, 8:20 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease

NCT03108222
View directory record Official record
Conditions
Chronic Kidney Disease Mineral and Bone Disorder
Interventions
Phosphorus Absorption Test
Other
Lead sponsor
Purdue University
Other
Eligibility
30 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Exercise Intolerance in Renal Failure

NCT01356966
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Tetrahydrobiopterin, Placebo, Folate
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Voiding Function After Mid-Urethral Slings With and Without Local Anesthetic: Randomized Controlled Trial

NCT01583166
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Bupivacaine, Saline, Epinephrine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Oct 17, 2026, 8:20 AM EDT